Pharma Mar, S.A. (BME:PHM)

Market Cap	1.60B
Revenue (ttm)	189.27M
Net Income (ttm)	42.01M
Shares Out	17.57M
EPS (ttm)	n/a
PE Ratio	38.15
Forward PE	23.87
Dividend	0.80 (0.91%)
Ex-Dividend Date	Jun 25, 2025

Volume	127,378
Average Volume	57,600
Open	88.00
Previous Close	88.25
Day's Range	86.85 - 93.55
52-Week Range	41.82 - 105.80
Beta	-0.09
RSI	61.86
Earnings Date	Oct 28, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.